The FDA has granted orphan drug designation (ODD) to a locally delivered formulation of irinotecan (ChemoSeed) for the ...

The therapeutic landscape for lymphoma is undergoing a transformative shift, moving away from traditional cytotoxic intensification toward more targeted, mechanism-driven strategi ...

Luciano Costa, MD, PhD, discusses the considerations for managing infection risk with bispecific antibodies in multiple ...

A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS versus placebo in high-grade uterine sarcomas. Median PFS was identical at 3.7 ...

Genetic assays have transformed how clinicians approach treatment decisions in breast cancer, offering both predictive and prognostic insight that helps tailor therapy to individu ...

Learn how ctDNA/MRD testing guides gastroesophageal cancer care—patient counseling, coverage hurdles, and what rising ctDNA means before scans. In an interview with Targeted Oncology, Rutika Mehta, MD ...

The recent FDA approval of teclistamab (Tecvayli) and daratumumab and hyaluronidase-fihj (Darzelex Faspro) marks a major shift in the treatment paradigm, moving powerful bispecifi ...

During a live event, Catherine Coombs, MD and participants debate frontline CLL BTK inhibitors: who benefits from continuous ...

Per-protocol survival improved versus earlier cutoffs, with 35% alive beyond 30 months and 13% beyond 50 months after two ...

For oncologists navigating the rapidly evolving landscape of renal cell carcinoma (RCC), the data presented at the 2026 ASCO ...

In a recent interview following the 2026 ASCO Genitourinary Cancers Symposium, Karie Danielle Keera Runcie, MD, assistant ...

Vincent Ma, MD, associate professor in the Department of Medicine at the University of Wisconsin School of Medicine and ...